



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(s): MAUL et al.

SERIAL NO.: 10/751,737 ART UNIT:

FILING DATE: 1/5/04 EXAMINER:

TITLE: USE OF SUBSTITUTED GAMMA-LACTONE COMPOUNDS AS
PHARMACEUTICAL PREPARATIONS

ATTORNEY
DOCKET NO.: 785-011642-US (C01)

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
(37 C.F.R. §1.97(b)(3))**

Sir:

This supplemental information disclosure statement is being filed before the mailing of a first Office Action on the merits.

The following information is being disclosed to the Patent and Trademark Office as information that may be material to the examination of the above-identified patent application. Applicants' Attorney is aware of the following references:

"Nitric Oxide Synthase Inhibition In Migraine" (pp.401-402)

"Nitric Oxide: From Basic Research To Clinical Applications"
(pp.47-49)

"Nitric Oxide Theory Of Migraine" (pp.28-33)

"Inhibition Of Nitric Oxide Synthase As A Potential Therapeutic Target" (pp. 191-220)

"Die Entdeckung Einiger Biologischer Wirkungen Von
Stickstoffmonoxid Und Seiner Rolle Für Die Zellkommunikation
(Nobel-Vortrag) (pp.1977-1989)


"Stickstoffmonoxid: Ein Einzigartiges Endogenes Signalmolekül In
Der Gefäßbiologie (Nobel-Vortrag) (pp.2003-2013)

Copies of these references are enclosed together with a Form PTO-1449.

The filing of this Statement is not to be construed as a representation that a search has been made regarding the claimed invention (37 C.F.R. §1.97(g)) or that no other possible material information exists. In addition, the filing of this Information Disclosure Statement is not to be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

The Commissioner is hereby authorized to charge payment for any fees associated with this communication or credit any over payment to Deposit Account No. 16-1350.

Respectfully submitted,



Geza C. Ziegler, Jr.

Reg. No. 44,004

PERMAN & GREEN, LLP
425 Post Road
Fairfield, CT 068424
Customer No. 2512

19 MARCH 2004
Date

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date indicated below as first class mail in an envelope address to the Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 3/19/04

signature: Shannon Watt
Shannon Watt



INFORMATION DISCLOSURE CITATION FORM FOR PATENT APPLICATION (FORM PTO-1449) (Substitute)		Docket No.: 785-011642-US(C01)		Serial No.: 10/751,737		
		Applicant(s): MAUL et al.				
		Filing Date: 1/5/04		Group:		
U.S. PATENTS						
Initials	Patent Number	Issue Date	Name		Class	Sub-class
			U.S. PATENT PUBLICATIONS			
Initials	Publication No.	Pub. Date	Name		Class	Sub-class
FOREIGN PATENT DOCUMENTS						
Initials	Document Number	Date	Country	Name		Translation? Yes/No/n/a
OTHER DOCUMENTS (Title, Author, Date, Pages, Etc., if known)						
	Lassen et al., "Nitric Oxide Synthase Inhibition in Migraine", February 8, 1997, Gloucester Gastroenterology Group, Gloucester, UK, pages 401-402.					
	Green et al., "Nitric Oxide: From Basic Research to Clinical Applications", February 2, 1999, DDT, vol. 4, Pages 47-49.					
	Thomsen et al., "Nitric Oxide Theory of Migraine", 1998, Clinical Neuroscience, pages 28-33.					
	Hobbs et al., "Inhibition of Nitric Oxide Synthase as a Potential Therapeutic Target", Annu. Rev. Pharmacol. Toxicol., 1999, pages 191-220.					
	Murad, "Die Entdeckung Einiger Biologischer Wirkungen Von Stickstoffmonoxid Und Seiner Rolle Fur Die Zellkommunikation (Nobel-Vortrag)", Angew. Chem., 1999, pages 1977-1989.					
	Ignaro, "Stickstoffmonoxid: Ein Einzigartiges Endogenes Signalmolekül In Der Gefäßbiologie (Nobel-Vortrag)" Angew. Chem., 1999, pages 2003-2013.					
Examiner's Signature:				Date Considered:		
Initial if reference was considered, whether or not citation is in conformance with MPEP. Mark through citation if not considered. Include a copy of this citation form with your next correspondence to the Applicant(s).						